{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:14:50Z","timestamp":1789391690069,"version":"build-2803163510"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by bone marrow fibrosis associated with substantial morbidity and mortality. The therapeutic landscape for MF has advanced with the development of Janus kinase inhibitors (JAKis) like ruxolitinib (RUX), fedratinib (FED), pacritinib (PAC), and momelotinib (MMB), aiming to alleviate symptoms and enhance patient comfort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A network meta-analysis was conducted to assess the efficacy and safety of eleven JAKi treatment regimens across nine randomized controlled trials (RCTs) with a total of 2340 participants. Outcomes were evaluated in terms of spleen volume reduction (SVR), total symptom score reduction (TSSR), hematological safety profiles, and overall survival (OS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>RUX and MMB were superior in achieving SVR and TSSR, with significant dose-response relationships observed. PAC and MMB were associated with a decreased risk of grade 3\/4 anemia and thrombocytopenia compared to other JAKis. However, no substantial benefits in OS were observed with newer JAKis compared to RUX. The poorer OS outcomes with certain PAC dosages were likely influenced by baseline patient characteristics, particularly severe cytopenias.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The introduction of JAKis significantly changed the treatment of MF. This meta-analysis reaffirms the core role of RUX and positions MMB as a potentially powerful alternative for treating symptoms and reducing spleen size. Meanwhile, MMB and PAC have a positive effect on anemia in MF while FED is more tolerable for patients with thrombocytopenia. However, it should be noted that these results are influenced by baseline patient characteristics, particularly cytopenias, which affects both management and overall survival. Therefore, there is an urgent need for personalized dosing strategies to optimize the balance between efficacy and safety, with careful consideration of patient-specific factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>, identifier CRD42023424179.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1403967","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T04:10:33Z","timestamp":1724991033000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative efficacy and hematologic safety of different dosages of JAK inhibitors in the treatment of myelofibrosis: a network meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Ke","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixuan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicong","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102435","article-title":"Impact of molecular profiling on the management of patients with myelofibrosis","volume":"109","author":"Pastor-Galan","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100706","article-title":"Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map","volume":"42","author":"Shallis","year":"2020","journal-title":"Blood Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/1179545X17695233","article-title":"Treatment of myelofibrosis: old and new strategies","author":"Iurlo","year":"2017","journal-title":"Clin Med Insights-Blood Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41408-021-00526-z","article-title":"Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: A systematic review and network meta-analysis","volume":"11","author":"Sureau","year":"2021","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01637-7","article-title":"Overall survival in the simplify-1 and simplify-2 phase 3 trials of momelotinib in patients with myelofibrosis","volume":"36","author":"Mesa","year":"2022","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: results from the pac203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.63","article-title":"A phase 2 randomized dose-ranging study of the Jak2-selective inhibitor fedratinib (Sar302503) in patients with myelofibrosis","volume":"5","author":"Pardanani","year":"2015","journal-title":"Blood Cancer J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7326\/m14-2385","article-title":"The prisma extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B13","volume-title":"R: A Language and Environment for Statistical Computing","year":"2009"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med DECISION MAKING"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00006","article-title":"Use of indirect and mixed treatment comparisons for technology assessment","volume":"26","author":"Sutton","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","article-title":"Cinema: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"New Engl J OF Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of comfort-I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of comfort-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 comfort-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556","article-title":"Jak inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"New Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from comfort-ii, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.087650","article-title":"Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 comfort studies","volume":"99","author":"Mesa","year":"2014","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from comfort-ii, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17727","article-title":"Updated results of the placebo-controlled, phase iii Jakarta trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis","volume":"195","author":"Pardanani","year":"2021","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (Persist-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.4418","article-title":"Simplify-1: A phase iii randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (Simplify 2): A randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"key":"B32","article-title":"Jak inhibitors in the treatment of myelofibrosis","volume":"20","author":"Levavi","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2135989","article-title":"Fedratinib: A pharmacotherapeutic option for Jak-inhibitor na\u00efve and exposed patients with myelofibrosis","volume":"23","author":"England","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2022.2139317","article-title":"Recent progress of jak inhibitors for hematological disorders","volume":"46","author":"Kirito","year":"2023","journal-title":"Immunol Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33541","article-title":"Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: frequency, therapeutic effects, and impact on outcome","volume":"127","author":"Palandri","year":"2021","journal-title":"Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26778","article-title":"Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival","volume":"98","author":"Gangat","year":"2023","journal-title":"Am J Hematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002662","article-title":"Acvr1\/Jak1\/Jak2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)01463-X","article-title":"Mpn-478 momentum: phase 3 randomized study of momelotinib (Mmb) versus danazol (Dan) in symptomatic and anemic myelofibrosis (Mf) patients previously treated with a Jak inhibitor","volume":"22","author":"Mesa","year":"2022","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-156936","article-title":"Pacritinib is a potent Acvr1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"140","author":"Oh","year":"2022","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18284","article-title":"Limited activity of fedratinib in myelofibrosis patients relapsed\/refractory to ruxolitinib 20\u2009Mg twice daily or higher: A real-world experience","volume":"198","author":"Gangat","year":"2022","journal-title":"Br J Haematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2043304","article-title":"Momelotinib reduces transfusion requirements in patients with myelofibrosis","volume":"63","author":"Mesa","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279415","article-title":"Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia","volume":"107","author":"Verstovsek","year":"2022","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1403967\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T04:10:39Z","timestamp":1724991039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1403967\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":43,"alternative-id":["10.3389\/fonc.2024.1403967"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1403967","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"article-number":"1403967"}}